U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07121946) titled 'A Phase 1 Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma' on Aug. 12.
Brief Summary: This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Non-Hodgkin Lymphoma Refractory/ Relapsed
DLBCL - Diffuse Large B Cell Lymphoma
Mantle Cell Lymphoma (MCL)
Follicular Lymphoma ( FL)
Margi...